Pulse Biosciences, Inc. (PLSE)
Pulse Biosciences, Inc. is focused on technology and products utilizing nansecond electric pulses to treat skin lesions and internal tumors. The technology originated in the labs of Professor Martin Gundersen within the Department of Electrical Engineering at the University of Southern California and the Frank Reidy Research Center for Bioelectrics at Old Dominion University. Pulse Biosciences’ IPO was in May 2016 and is listed on the NASDAQ as PLSE.
Varocto, Inc. was founded in 2014 as an ophthalmological imaging company. Using Optical Coherence Tomography (OCT), the company’s technology is able to provide angiographic images of the human retina. This imaging technology is especially well-suited for the clinical diagnosis of Diabetic Retinopathy (DR) and Age-related Macular Degeneration (AMD). The technology is rapid, noninvasive, and provides significant advantages over current methods of retinal angiography. The technology was developed by AMI-USC in partnership with the Translational Imaging Center at USC under the direction of Professor Scott Fraser. The company was financed through a private equity investment. Varocto was acquired in May 2019.
Proa Medical, Inc.
Proa Medical, Inc. is a women’s health medical device company spun out from AMI-USC that raised private capital from investors in several countries. Proa commercially launched its first product, a patented surgical retractor for post-partum visualization and repairs of the birth canal and perineum, which received favorable feedback from physicians. The company merged with Pelv-Ice, LLC in November 2020.